The company's platform relies on a method called RABID-seq that combines barcoded viral tracing with single-cell RNA-seq to study interactions between brain cells.
The application was based on results from a Phase I/II trial in which Hyrnuo demonstrated a 71 percent response rate.
The approval is for DEB patients from birth and allows for flexible administration at home by patients or caregivers.
Investigators will analyze CTCs from colon, gastrointestinal, and lung cancer patients to help understand how they respond to exercise regimens.
Investigators will analyze CTCs from colon, gastrointestinal, and lung cancer patients to help understand how they respond to exercise regimens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results